We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $-2.3 | — | — | $360 | — | 예정 |
| FY2025 Q3 | 2025. 09. 30. | 시각 미정 | — | $2.1 | — | — | $351K | 보고됨 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $3.75 | — | — | $0 |
Consensus PT $22 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 03. 14. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
| 2025. 09. 24. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2024 Q2 | 2023. 06. 30. | 시각 미정 | — | $-0.19 | — | — | $125.95M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 25,749 | $383.15M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 18,794 | $166.7M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Stored first · Google News · Yahoo Finance (English)
[8-K] Seres Therapeutics, Inc. Reports Material Event - Stock Titan
[8-K] Seres Therapeutics, Inc. Reports Material Event Stock Titan
Seres Therapeutics stock (US81750R1023): what’s next after microbiome setback and restructuring? - AD HOC NEWS
Seres Therapeutics stock (US81750R1023): what’s next after microbiome setback and restructuring? AD HOC NEWS
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan - Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan - Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan Stock Titan